HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60

Benzinga · 2d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $65 to $60.